Franklin Covey Co. (NYSE: FC) is a small-cap leadership and organizational performance company that has spent the past two years rebuilding its Enterprise North America sales motion after a sharp fiscal 2024 peak. The fiscal 2025 fiscal year (ended August 31, 2025) saw consolidated revenue fall 7% to $267.1 million and net income collapse to $3.1 million from $23.4 million as the North America segment absorbed canceled government contracts, geopolitical pressure in Europe and Asia, and a self-inflicted transition to a new go-to-market structure. The third quarter of fiscal 2026 (ended May 31, 2026) marked a credible inflection: consolidated revenue grew 1% to $67.8 million, gross margin compressed to 73.9% from 76.5%, but operating income flipped to $4.2 million from a $2.2 million loss, and Adjusted EBITDA rose 14% to $8.3 million. The argument for Franklin Covey is that subscription invoiced amounts are now growing again after three quarters of decline, that the Education Division's Leader in Me program continues to add schools (over 8,000 globally as of May 2026), and that the buyback is meaningfully shrinking the share count while a $157.1 million remaining performance obligation (RPO) provides visibility into deferred revenue recognition.
The strongest counterargument is that fiscal 2026 to date is still a year of execution, not a year of acceleration. Year-to-date revenue is down 2% to $191.5 million, the company is still reporting a nine-month net loss, and gross margin is under pressure from higher delivery and product amortization costs. The stock at $20.08 trades at 14.3x forward earnings estimates and roughly 13x the consensus 2026 Adjusted EBITDA, which is reasonable for a sub-3% organic growth name but does not yet price a true reacceleration. The thesis works if North America invoiced amounts continue to grow and translate into reported revenue in fiscal 2027; it fails if government spending pressure re-intensifies, if Education's state funding cuts spread, or if the new go-to-market strategy takes longer than the company expects to reach its prior productivity levels.
The position-sizing implication is that Franklin Covey is a name to own for the inflection rather than the current quarter, with the buyback providing a near-term floor under the per-share metrics and the deferred revenue base providing a tailwind for fiscal 2027 reported results. Investors who underweight the buyback or the deferred revenue base will underweight the stock, and investors who overweight the 1% current-quarter revenue growth rate will pass. The window to build a position at a sub-8x trailing Adjusted EBITDA multiple and a deferred-revenue-to-market-cap ratio above 40% is likely narrow, and the report concludes that the current valuation offers an attractive entry for a 2-3 year horizon.